Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (990)	2/4/2000 6:23:00 PM
From: scott_jiminez	Read Replies (1) \| Respond to of 4474

PB - The following thought is likely to have a significant implausibility: Wouldn't it be 'interesting' if Ariad could substitute a 'glucose-response-element' (receptor?) for the FKBP sites in the insulin construct. This 'GRE' would have to be quantitatively regulateable just like the AP1903 (i.e. Rapamycin)/FKBP system is. Thus, instead of a diabetic needing to time an ingestion of the dimerizer with anticipated glucose levels, endogenous/systemic glucose would ITSELF be the trigger. The need for patient 'participation' would be eliminated and RAPID would truly come close to replacing the faulty islet cell function. A 'self-regulating' ARGENT-based system with glucose as the anti-dimerizer. No pills, no needles, no nothing. Wouldn't it be interesting...